|
1
|
Gourgiotis S, Kocher HM, Solaini L,
Yarollahi A, Tsiambas E and Salemis NS: Gallbladder cancer. Am J
Surg. 196:252–264. 2008. View Article : Google Scholar
|
|
2
|
Lazcano-Ponce EC, Miquel JF, Muñoz N,
Herrero R, Ferrecio C, Wistuba II, Alonso de Ruiz P, Aristi Urista
G and Nervi F: Epidemiology and molecular pathology of gallbladder
cancer. CA Cancer J Clin. 51:349–364. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Reddy SK and Clary BM: Surgical management
of gallbladder cancer. Surg Oncol Clin North Am. 18:307–324. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li LD, Zhang SW, Lu FZ, Mu R, Sun XD and
Huangpu XM: Research on characteristics of mortality spectrum and
type composition of malignant tumors in China. Zhonghua Zhongliu
Zazhi. 19:323–328. 1997.PubMed/NCBI
|
|
5
|
Hsing AW, Gao YT, Devesa SS, Jin F and
Fraumeni JF Jr: Rising incidence of biliary tract cancers in
Shanghai, China. Int J Cancer. 75:368–370. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chakravarty KD, Yeh CN, Jan YY and Chen
MF: Factors influencing long-term survival in patients with T3
gallbladder adenocarcinoma. Digestion. 79:151–157. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Konstantinidis IT, Deshpande V, Genevay M,
Berger D, Fernandez-del Castillo C, Tanabe KK, Zheng H, Lauwers GY
and Ferrone CR: Trends in presentation and survival for gallbladder
cancer during a period of more than 4 decades: a single-institution
experience. Arch Surg. 144:441–447. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ishii H, Furuse J, Yonemoto N, Nagase M,
Yoshino M and Sato T: Chemotherapy in the treatment of advanced
gallbladder cancer. Oncology. 66:138–142. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Morise Z, Sugioka A, Tanahashi Y, Okabe Y,
Ikeda M, Kagawa T and Takeura C: Treatment of patients with
unresectable advanced carcinoma of biliary tract chemotherapy and
surgical resection. Anticancer Res. 29:1783–1786. 2009.PubMed/NCBI
|
|
10
|
Mahantshetty UM, Palled SR, Engineer R,
Homkar G, Shrivastava SK and Shukla PJ: Adjuvant radiation therapy
in gallbladder cancers: 10 years experience at Tata Memorial
Hospital. J Cancer Res Ther. 2:52–56. 2006.PubMed/NCBI
|
|
11
|
Mojica P, Smith D and Ellenhorn J:
Adjuvant radiation therapy is associated with improved survival for
gallbladder carcinoma with regional metastatic disease. J Surg
Oncol. 96:8–13. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shukla PJ and Barreto SG: Gallbladder
cancer: we need to do better! Ann Surg Oncol. 16:2084–2085.
2009.
|
|
13
|
Maniotis AJ, Folberg R, Hess A, Seftor EA,
Gardner LM, Pe’er J, Trent JM, Meltzer PS and Hendrix MJ: Vascular
channel formation by human melanoma cells in vivo and in vitro:
vasculogenic mimicry. Am J Pathol. 155:739–752. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Warso MA, Maniotis AJ, Chen X, Majumdar D,
Patel MK, Shilkaitis A, Gupta TK and Folberg R: Prognostic
significance of periodic acid-Schiff-positive patterns in primary
cutaneous melanoma. Clin Cancer Res. 7:473–477. 2001.PubMed/NCBI
|
|
15
|
Shirakawa K, Wakasugi H, Heike Y, Watanabe
I, Yamada S, Saito K and Konishi F: Vasculogenic mimicry and
pseudo-comedo formation in breast cancer. Int J Cancer. 99:821–828.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sood AK, Fletcher MS, Zahn CM, Gruman LM,
Coffin JE, Seftor EA and Hendrix MJ: The clinical significance of
tumor cell-lined vasculature in ovarian carcinoma: implications for
anti-vasculogenic therapy. Cancer Biol Ther. 1:661–664. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sun B, Zhang S, Zhang D, Du J, Guo H, Zhao
X, Zhang W and Hao X: Vasculogenic mimicry is associated with high
tumor grade, invasion and metastasis, and short survival in
patients with hepatocellular carcinoma. Oncol Rep. 16:693–698.
2006.PubMed/NCBI
|
|
18
|
Guzman G, Cotler SJ, Lin AY, Maniotis AJ
and Folberg R: A pilot study of vasculogenic mimicry
immunohistochemical expression in hepatocellular carcinoma. Arch
Pathol Lab Med. 131:1776–1781. 2007.PubMed/NCBI
|
|
19
|
Li M, Gu Y, Zhang Z, Zhang S, Zhang D,
Saleem AF, Zhao X and Sun B: Vasculogenic mimicry: a new prognostic
sign of gastric adenocarcinoma. Pathol Oncol Res. 16:259–266. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Baeten CI, Hillen F, Pauwels P, de Bruine
AP and Baeten CG: Prognostic role of vasculogenic mimicry in
colorectal cancer. Dis Colon Rectum. 52:2028–2035. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hess AR, Seftor EA, Seftor RE and Hendrix
MJ: Phosphoinositide 3-kinase regulates membrane Type 1-matrix
metalloproteinase (MMP) and MMP-2 activity during melanoma cell
vasculogenic mimicry. Cancer Res. 63:4757–4762. 2003.PubMed/NCBI
|
|
22
|
Seftor RE, Seftor EA, Koshikawa N, Meltzer
PS, Gardner LM, Bilban M, Stetler-Stevenson WG, Quaranta V and
Hendrix MJ: Cooperative interactions of laminin 5 gamma 2 chain,
matrix metalloproteinase-2, and membrane
type-1-matrix/metalloproteinase are required for mimicry of
embryonic vasculogenesis by aggressive melanoma. Cancer Res.
61:6322–6327. 2001.
|
|
23
|
Seftor RE, Seftor EA, Kirschmann DA and
Hendrix MJ: Targeting the tumor microenvironment with chemically
modified tetracyclines: inhibition of laminin 5 gamma2 chain
promigratory fragments and vasculogenic mimicry. Mol Cancer Ther.
1:1173–1179. 2002.
|
|
24
|
Sood AK, Fletcher MS, Coffin JE, Yang M,
Seftor EA, Gruman LM, Gershenson DM and Hendrix MJ: Functional role
of matrix metalloproteinases in ovarian tumor cell plasticity. Am J
Obstet Gynecol. 190:899–909. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hess AR, Seftor EA, Gardner LM,
Carles-Kinch K, Schneider GB, Seftor RE, Kinch MS and Hendrix MJ:
Molecular regulation of tumor cell vasculogenic mimicry by tyrosine
phosphorylation: role of epithelial cell kinase (Eck/EphA2). Cancer
Res. 61:3250–3255. 2001.PubMed/NCBI
|
|
26
|
Margaryan NV, Strizzi L, Abbott DE, Seftor
EA, Rao MS, Hendrix MJ and Hess AR: EphA2 as a promoter of melanoma
tumorigenicity. Cancer Biol Ther. 8:279–288. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hess AR, Margaryan NV, Seftor EA and
Hendrix MJ: Deciphering the signaling events that promote melanoma
tumor cell vasculogenic mimicry and their link to embryonic
vasculogenesis: role of the Eph receptors. Dev Dyn. 236:3283–3296.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hess AR and Hendrix MJ: Focal adhesion
kinase signaling and the aggressive melanoma phenotype. Cell Cycle.
5:478–480. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hess AR, Postovit LM, Margaryan NV, Seftor
EA, Schneider GB, Seftor RE, Nickoloff BJ and Hendrix MJ: Focal
adhesion kinase promotes the aggressive melanoma phenotype. Cancer
Res. 65:9851–9860. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ruf W, Seftor EA, Petrovan RJ, Weiss RM,
Gruman LM, Margaryan NV, Seftor RE, Miyagi Y and Hendrix MJ:
Differential role of tissue factor pathway inhibitors 1 and 2 in
melanoma vasculogenic mimicry. Cancer Res. 63:5381–5389.
2003.PubMed/NCBI
|
|
31
|
Wang JY, Sun T, Zhao XL, Zhang SW, Zhang
DF, Gu Q, Wang XH, Zhao N, Qie S and Sun BC: Functional
significance of VEGF-a in human ovarian carcinoma: role in
vasculogenic mimicry. Cancer Biol Ther. 7:758–766. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ge CY and Fan YZ: Vasculogenic mimicry and
its molecules signaling pathways. Chin Med Abstr (Surg).
15:344–350. 2006.
|
|
33
|
Fan YZ and Sun W: Molecular regulation of
vasculogenic mimicry in tumors and potential tumor-target therapy.
World J Gastrointest Surg. 2:117–127. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fan YZ, Sun W, Zhang WZ and Ge CY:
Vasculogenic mimicry in human primary gallbladder carcinoma and
clinical significance thereof. Zhonghua Yi Xue Za Zhi. 87:145–149.
2007.PubMed/NCBI
|
|
35
|
Sun W, Shen ZY, Zhang H, Fan YZ, Zhang WZ,
Zhang JT, Lu XS and Ye C: Overexpression of HIF-1α in primary
gall-bladder carcinoma and its relation to vasculogenic mimicry and
unfavourable prognosis. Oncol Rep. 27:1990–2002. 2012.
|
|
36
|
Sun W, Fan YZ, Zhang WZ and Ge CY: A pilot
histomorphology and hemodynamic of vasculogenic mimicry in
gallbladder carcinomas in vivo and in vitro. J Exp Clin Cancer Res.
30:462011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Link W, Rosado A, Fominaya J, Thomas JE
and Carnero A: Membrane localization of all class I PI3-kinase
isoforms suppresses c-Myc-induced apoptosis in Rat1 fibroblasts via
Akt. J Cell Biochem. 95:979–989. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
McCawley LJ and Matrisian LM: Matrix
metalloproteinases: multifunctional contributors to tumor
progression. Mol Med Today. 6:149–156. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Noel A, Gilles C, Bajou K, Devy L, Kebers
F, Lewalle JM, Maquoi E, Munaut C, Remacle A and Foidart JM:
Emerging roles for proteinases in cancer. Invasion Metastasis.
17:221–239. 1997.PubMed/NCBI
|
|
40
|
Stetler-Stevenson WG: Matrix
metalloproteinases in angiogenesis: a moving target for therapeutic
intervention. J Clin Invest. 103:1237–1241. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Seiki M: Membrane-type matrix
metalloproteinases. APMIS. 107:137–143. 1999. View Article : Google Scholar
|
|
42
|
Chang C and Werb Z: The many faces of
metalloproteases: cell growth, invasion, angiogenesis and
metastasis. Trends Cell Biol. 11:S37–S43. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lafleur MA, Handsley MM, Knauper V, Murphy
G and Edwards DR: Endothelial tubulogenesis within fibrin gels
specifically requires the activity of membrane-type-matrix
metalloproteinases (MT-MMPs). J Cell Sci. 115:3427–3438.
2002.PubMed/NCBI
|
|
44
|
Koike T, Vernon RB, Hamner MA, Sadoun E
and Reed MJ: MT1-MMP, but not secreted MMPs, influences the
migration of human microvascular endothelial cells in 3-dimensional
collagen gels. J Cell Biochem. 86:748–758. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Haas TL, Davis SJ and Madri JA:
Three-dimensional type I collagen lattices induce coordinate
expression of matrix metalloproteinases MT1-MMP and MMP-2
inmicrovascular endothelial cells. J Biol Chem. 273:3604–3610.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Hendrix MJ, Seftor EA, Kirschmann DA,
Quaranta V and Seftor RE: Remodeling of the microenvironment by
aggressive melanoma tumor cells. Ann NY Acad Sci. 995:151–161.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Brantley DM, Cheng N, Thompson EJ, Lin Q,
Brekken RA, Thorpe PE, Muraoka RS, Cerretti DP, Pozzi A, Jackson D,
Lin C and Chen J: Soluble Eph A receptors inhibit tumor
angiogenesis and progression in vivo. Oncogene. 21:7011–7026. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Cheng N, Brantley DM, Liu H, Lin Q,
Enriquez M, Gale N, Yancopoulos G, Cerretti DP, Daniel TO and Chen
J: Blockade of EphA receptor tyrosine kinase activation inhibits
vascular endothelial cell growth factor-induced angiogenesis. Mol
Cancer Res. 1:2–11. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Miao H, Burnett E, Kinch M, Simon E and
Wang B: Activation of EphA2 kinase suppresses integrin function and
causes focal-adhesion-kinase dephosphorylation. Nat Cell Biol.
2:62–69. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Hendrix MJ, Seftor EA, Meltzer PS, Gardner
LM, Hess AR, Kirschmann DA, Schatteman GC and Seftor RE: Expression
and functional significance of VE-cadherin in aggressive human
melanoma cells: role in vasculogenic mimicry. Proc Natl Acad Sci
USA. 98:8018–8023. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Hess AR, Seftor EA, Gruman LM, Kinch MS,
Seftor RE and Hendrix MJ: VE-cadherin regulates EphA2 in aggressive
melanoma cells through a novel signaling pathway: implications for
vasculogenic mimicry. Cancer Biol Ther. 5:228–233. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Schaller MD: Paxillin: a focal
adhesion-associated adaptor protein. Oncogene. 20:6459–6472. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Stetler-Stevenson WG, Krutzsch HC and
Liotta LA: TIMP-2, a new member of the metalloproteinase inhibitor
family. J Biol Chem. 264:17374–17378. 1989.PubMed/NCBI
|
|
54
|
Goldberg GI, Marmer BL, Grant GA, Eisen
AZ, Wilhelm S and He C: Human 72-kDa type IV collagenase forms a
complex with a tissue inhibitor of metalloproteinase inhibitor.
Proc Nati Acad Sci USA. 86:8207–8211. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Albini A, Melchiori A, Santi L, Liotta LA,
Brown PD and Stetler-Stevenson WG: Tumor cell invasion inhibited by
TIMP-2. J Natl Cancer Inst. 83:775–779. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Liotta LA and Stetler-Stevenson WG: Tumor
invasion and metastasis: an imbalance of positive and negative
regulation. Cancer Res. 51(Suppl): S5054–S5059. 1991.PubMed/NCBI
|
